OA01.07 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations

Sunvozertinib (DZD9008) is a rationally designed EGFR Exon20ins inhibitor with wildtype selectivity. Results from the ongoing phase 1/2 studies showed sunvozertinib’s strong anti-tumor activity and encouraging safety profile. Based on these data, sunvozertinib was granted the Breakthrough Therapy Designation by both US FDA and China NMPA. Here we present sunvozertinib’s safety and efficacy results in advanced NSCLC patients with EGFR Exon20ins post platinum-based chemotherapies.